Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Jun 04, 2020 12:47pm

84 Views

Post# 31112213

RE:RE:RE:RE:RE:Buy out Coming

Hey Max,
that's not true about using your tax losses in year 1, they carry over indefinitely but there are provisions for there uses. The CRA is definitely involved in how they are used and regulate specifics. Cipher is entitled to sell them as part of a sale but I think it would be in everyone's best interest that they are sold with something that incurred a capital gain to off set the loss in reporting. Still the NOLs are definitely worth 20-30 million in future capital gains from my vantage point.

Bullboard Posts

E3 inches closer to Alberta's first lithium production plant